Companies
Adidas
brought Mylo mycelium-leather uppers to a named retail model, the Stan Smith Mylo, applying a mycelium-based leather alternative to one of its highest-volume sneaker silhouettes rather than a standalone concept shoe.
- Country
- Germany
mycelium-leather-upper
eu
Coverage
| EU | US | |
|---|---|---|
| fibers-textiles | ✓ | ✓ |
Regulatorsepareach
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Bolt Threads has raised over $400 million in total funding as a private company, including a Series E round of $253 million in 2021. Additional recent financing includes $7 million in convertible notes (2023), $28 million in PIPE and bridge financing (2024), and various 2025 financing actions. | sacra.com · sayinstitute.eu · vogue.com |
| Capacity | 1 million square feet per year (before production of Mylo ceased in 2023) | sayinstitute.eu · vogue.com |
| Certification | 60 percent to 85 percent bio-based under the German DIN-Geprüft standard | wwd.com |
| Regulatory approval | No regulatory approvals for Mylo were reported; production was discontinued in 2023. | businessoffashion.com · sec.gov |
| Production site | Pilot production facilities in various locations; MME in the Netherlands (mushroom farming); Heller Leather in Germany (finishing) | forbes.com · sayinstitute.eu · sec.gov |
| Headcount | Personnel headcount was reduced in 2023 following the discontinuation of Mylo production. | content.edgar-online.com · sec.gov |
| Revenue | Approximately $1.4 million for the full year 2024; $3.4 million for the full year 2023. | morningstar.com |
Independent sources: businessoffashion.com · content.edgar-online.com · forbes.com · morningstar.com · sacra.com · sayinstitute.eu · sec.gov · vogue.com · wwd.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bio-footwear (mycelium, algae foam, pineapple leaf) | fibers-textiles | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.